Management of high-grade bone sarcomas over two decades: The Norwegian Radium Hospital experience

Acta Oncologica

Volumn 45, Issue 1, 2006, Pages 38-46

  Aksnes, Liv Hege ^a   Hall, Kirsten Sundby ^a   Folleraas, Gunnar ^a   Stenwig, Anna Elisabeth ^a   Bjerkehagen, Bodil ^a   Taksdal, Ingeborg ^a   Winderen, Mette ^a   Bruland, Øyvind Sverre ^a   Sæter, Gunnar ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; AMPUTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; DISEASE SEVERITY; EWING SARCOMA; FEMALE; HOSPITAL; HUMAN; LIMB TUMOR; MALE; MEDICAL AUDIT; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NORWAY; OSTEOSARCOMA; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANCER CARE FACILITIES; CHILD; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NORWAY; OSTEOSARCOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA, EWING'S; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 32244435967     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500466624     Document Type: Article

References (20)

1. Bauer HC, Alvegard TA, Berlin O, et al. The Scandinavian Sarcoma Group Register. Acta Orthop Scand 1999;70(Suppl 285):41-4.
2. Alvegard TA, Rydholm A. The Scandinavian Sarcoma Group. Twenty years experience. Acta Orthop Scand 1999;70(Suppl 285).
3. Unni KK, Dahlin DC. Grading of bone tumors. Semin Diagn Pathol 1984;1:165-72.
4. Inwards CY, Unni KK. Classification and grading of bone sarcomas. Hematol Oncol Clin North Am 1995;9:545-69.
5. Saeter G, Alvegard TA, Elomaa I, Stenwig AE, Holmstrom T, Solheim OP. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: A Scandinavian Sarcoma Group study. J Clin Oncol 1991;9(10):1766-75.
6. Saeter G, Wiebe T, Wiklund T, et al. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand 1999;70(Suppl 285):74-82.
7. Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: Prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003;39:488-94.
8. Bacci G, Ferrari S, Longhi A, et al. High dose ifosfamide in combination with high dose metothrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma:preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 2002;14(2):198-206.
9. Smeland S, Bacci G, Ferrari S, et al. Neoadjuvant chemotherapy with high-dose ifosfamide added to methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity. A joint study by the Italian (ISG) and Scandinavian sarcoma groups. Proceedings of ASCO 2003;22:817 (abstr).
10. Nilbert M, Saeter G, Elomaa I, et al. Ewing's sarcoma treatment in Scandinavia 1984-1990-ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV. Acta Oncol 1998;37:375-8.
11. Elomaa I, Blomqvist CP, Saeter G, et al. Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer 2000;36:875-80.
12. Rosito P, Mancini AF, Rondelli R, et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: A preliminary report of 6 years of experience. Cancer 1999;86:421-8.
13. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997;33:1725-31.
14. Stiller CA. Survival of patients with cancer. Those included in clinical trials do better. BMJ 1989;299:1058-9.
15. Elomaa I, Blomqvist C, Saeter G, et al. Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand 1999;70(Suppl 285):69-73.
16. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family oftumors:current status and outlook for the future. Med Pediatr Oncol 2003;40:276-87.
17. Burdach S, Meyer-Bahlburg A, Laws HJ, et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: Results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003;21:3072-8.
18. Saeter G, Høie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995;75:1084-93.
19. Gobel V, Jurgens H, Etspuler G, et al. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 1987;113:187-91.
20. Sæter G, Bruland ØS, Follerås G, et al. Extremity and non-extremity high-grade osteosarcoma. The Norwegian Radium Hospital experience during the modern chemotherapy era. Acta Oncol 1996;35(Suppl 8):129-34.